Estrogen modulators, such as selective estrogen receptor modulators (SERMs) and selective estrogen receptor downregulators (SERDs), have gained attention for their potential in treating estrogen receptor-positive (ER+) breast cancer. This evidence concerns the gene ESR1 and breast carcinoma.